Novasorb is a patented eye drop
formulation platform developed to optimise the interaction of the eye drop-the
cationic nanoemulsion-with the different layers of the tear film, mainly with the tear film lipid layer (TFLL), and the ocular surface.
The composition of
the cationic nanoemulsion was designed to mimic the attributes and functions of
the tear film and TFLL, and take advantage of the negatively-charged mucin
layer covering the corneal and conjunctival epithelium, to increase its
spreading and residence time on the ocular surface. Consequently, Novasorb®-based artificial tears (AT, e.g. Cationorm®) are functionally and mechanically very close to a healthy tear film; with an iso-osmolar to slightly
hypo-osmolar aqueous phase, polar (cetalkonium chloride, CKC) and nonpolar
(mineral oils or medium chain triglycerides, MCT) lipids, and surfactants (e.g.
Tyloxapol and Poloxamer) that mimic the surface active proteins present at the
interface with the TFLL.
No comments:
Post a Comment